RoosterBio accelerates human mesenchymal stem/stromal cell (hMSC) and extracellular vesicle (EV) product and process development to fuel the rapid commercialization of scalable regenerative cures. Our high-quality hMSCs, bioprocess media, genetic engineering tools, and EV production solutions are paired with expert bioprocessing knowledge to progress therapeutic developers from concept to first-in-human testing and commercial manufacturing at reduced cost and increased productivity. With optimized, scalable processes, Type 2 Drug Master Files, and cGMP products, we have enabled therapeutic programs to traverse their path to clinical translation in under 1 year.

RoosterBio is driven by our client's success and creating a world where safe and effective regenerative medicines are rapidly developed and widely available on a global scale.




5295 Westview Drive Suite 275

Frederick, MD 21703


Phone: 240-831-4914


  • When MSCs are genome-edited, it will inevitably be done with cell therapy in mind and should involve complementary breakthroughs to scale up and industrialize gene delivery.

  • Available in multiple tissues origins and from multiple donors, RoosterBio’s human mesenchymal stem/stromal cells (hMSCs) are sourced under strict guidelines, manufactured with highly standardized processes, and supported by 1st in class characterization.

  • Eliminate media exchanges with RoosterNourish™ hMSC expansion medium and RoosterReplenish™ in-process bioreactor feed.

  • Standardize the production of exosomes/extracellular vesicles with a translation-friendly, scalable system designed to streamline your process from cell-expansion to optimized EV collection yields.

  • RoosterGEM™ is a complete genetic engineering medium that allows researchers and product developers to confidently engineer their therapeutic product with simplified end-to-end processes.

  • RoosterBio’s Cell & Media Kits allow you to economically screen multiple hMSC donors or tissues and rapidly evaluate RoosterBio’s media exchange-free system.

  • RoosterBio’s CliniControl™ products include human mesenchymal stem/stromal cells, bioprocess expansion media, and exosome/extracellular vesicle production media manufactured in compliance with cGMPs and supported by U.S. FDA Type II Master Files.

  • The path to IND approval for cell-based therapies can be challenging and time-consuming with strict regulatory requirements.

  • Advanced therapy programs are complex arrays of upstream and downstream processes that must reliably work together to produce consistent products worthy of clinical use.